Multiple Defect-Induced High-Resolution Near-Infrared Mechanoluminescent Materials for Non-Destructive Detection of Blood Glucose and Lipids

© 2024 Wiley‐VCH GmbH.

Bibliographische Detailangaben
Veröffentlicht in:Advanced materials (Deerfield Beach, Fla.). - 1998. - 36(2024), 50 vom: 06. Dez., Seite e2408508
1. Verfasser: Wu, Sheng (VerfasserIn)
Weitere Verfasser: Zhou, Guangyu, Wu, Yafen, Xiong, Puxian, Xiao, Binli, Zhou, Zhiyao, Xiao, Yao, Shao, Peishan, Wang, Shouping, Shao, Zhigang, Wang, Yinzhen, Wang, Feifei
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2024
Zugriff auf das übergeordnete Werk:Advanced materials (Deerfield Beach, Fla.)
Schlagworte:Journal Article Cr3+ multiple defect near infrared mechanoluminescence non‐destructive detection persistent luminescence Blood Glucose Lipids Luminescent Agents
Beschreibung
Zusammenfassung:© 2024 Wiley‐VCH GmbH.
Mechanoluminescence (ML) materials, known for their ability to convert mechanical energy into light, are increasingly recognized for their potential applications, such as in intelligent stress sensing, in vivo bioimaging, and stress non-destructive monitoring. However, the low signal-to-noise ratio (SNR) and narrow-band emission of single-defect-induced ML materials usually limit their biological-related practical applications. Here, these limitations will be addressed by modulating the microstructure evolution in Y3Ga3MgSiO12:Cr3+ through the [Si4++Mg2+] → [Ga3++Ga3+] chemical substitution strategy. Density functional theory (DFT) calculation reveals the defect types and dynamic charge migration processes. In addition, Y3Ga3MgSiO12: Cr3+ with continuously distributed "shallow-deep" defects (0.68-1.61 eV) can avoid persistent luminescence (PersL) and bright-field environment interference. Herein, such high SNR near-infrared broadband ML emission may provide a reliable way for high-quality biological non-destructive sensing and detection. Finally, benefiting from the different absorption of ML signals in glucose/lipid, one may find a novel non-invasive blood glucose/lipid testing technology in patients
Beschreibung:Date Completed 12.12.2024
Date Revised 12.12.2024
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-4095
DOI:10.1002/adma.202408508